The Budget Impact Analysis of Adopting Direct Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation Patients in Malawi
Value in Health Regional Issues · 2023
DOI: 10.1016/j.vhri.2023.04.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health Regional Issues, 2023. Verfasst von Mirriam M Chikumbanje und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Life Sciences and Education, Learna Ltd in Partnership with University of South Wales, Cardiff, Wales, UK. Electronic address: mirriammukh…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Themen: Schlaganfall
Abstract (Originalsprache)
OBJECTIVES: This study aimed to estimate the budget impact of adopting direct oral anticoagulants (DOACs) for stroke prevention in patients with nonvalvular atrial fibrillation in Malawi after the inclusion of DOACs in the World Health Organization's essential medicine list. METHODS: A model was developed in Microsoft Excel. An eligible population of 201 491 was adjusted with 0.05 % incidence rate and mortality rates yearly according to the treatments. The model estimated the implication of supplementing rivaroxaban or apixaban to the standard treatment mix (also the comparator), thus warfarin and aspirin. The current market share of 43% aspirin and 57% warfarin was adjusted proportionally with 10% DOAC uptake in the first year and 5% annually over the subsequent 4 years. Clinical events of stroke and major bleeding from the ROCKET-AF and ARISTOTLE trials were used because health outcome indicators affect resource utilization. The analysis was conducted solely from the Malawi Ministry of Health perspective and it considered direct costs over 5 years. The sensitivity analysis involved varying drug costs, population, and care costs from both public and private sectors. RESULTS: The research suggests that despite potential savings of $6 644 141 to $6 930 812 in stroke care because of fewer stroke events, the total Ministry of Health healthcare budget (approximately $260 400 000) may increase by between $42 488 342 to $101 633 644 in 5 years because drug acquisition costs are greater than savings. CONCLUSIONS: With a fixed budget and current DOACs prices, Malawi can consider using DOACs in patients at the highest risk while waiting for cheaper generic versions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Life Sciences and Education, Learna Ltd in Partnership with University of South Wales, Cardiff, Wales, UK. Electronic address: mirriammukhuna@gmail.com.
- Faculty of Life Sciences and Education, Learna Ltd in Partnership with University of South Wales, Cardiff, Wales, UK.
Zitieren
APA
Chikumbanje, M. M., Raza, S., & Barham, L. (2023). The Budget Impact Analysis of Adopting Direct Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation Patients in Malawi. Value in Health Regional Issues. https://doi.org/10.1016/j.vhri.2023.04.005
Vancouver
Chikumbanje MM, Raza S, Barham L. The Budget Impact Analysis of Adopting Direct Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation Patients in Malawi. Value in Health Regional Issues. 2023. doi:10.1016/j.vhri.2023.04.005
BibTeX
@article{Chikumbanje2023,
author = {Chikumbanje, Mirriam M and Raza, Syed and Barham, Leela},
title = {The Budget Impact Analysis of Adopting Direct Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation Patients in Malawi},
journal = {Value in Health Regional Issues},
year = {2023},
doi = {10.1016/j.vhri.2023.04.005}
}
EUVIMED